Literature DB >> 31115239

Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.

Jing-Ya Zhang, Peng Ge, Peng-Yu Zhang, Meng Zhao, Li Ren.   

Abstract

BACKGROUND: Accumulating evidence has revealed that inflammation might play an important role in the genesis and development of cancer. High levels of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ration (PLR) are parameters of systemic inflammation which have been identified to be associated with poor prognosis in PCa. Bone is one of the most common sites of metastasis from prostate cancer; however, there are few studies concerning the correlation of NLR, PLR, and bone metastases in PCa. The aim of this study was to evaluate the performance of neutrophil to lymphocyte ratio (NLR) or platelet to lymphocyte (PLR) in diagnosis of bone metastasis of prostate cancer (PCa).
METHODS: Data of 74 PCa patients without metastases, 51 PCa patients with bone metastases, and 43 patients with benign prostatic hypertrophy (BPH) were retrospectively reviewed. The difference of patients' clinical and laboratory characteristics of the three groups was comparatively studied. ROC analysis was used to evaluate the benefit of adding NLR or PLR to prostate specific antigen (PSA) in prediction of bone metastases. Depending on this cutoff value, patients were divided into high-NLR or low-NLR group, high-PLR or low-PLR group.
RESULTS: There were significant differences in NLR and PLR between groups with bone metastases and without bone metastases (p = 0.044; p = 0.030), while there was no significant difference between NLR and PLR of the patients with localized prostate cancer and BPH (p = 0.462; p = 0.102). NLR and PLR were correlated with PSA level in the patients with prostate cancer (p = 0.006, r = 0.247; p = 0.025, r = 0.200). The distribution of PSA showed significant differences between the high-NLR and low-NLR group, as well as between the high-PLR and low-PLR group. By applying the ROC curve method, the AUC values of PSA with NLR or PLR were 0.725 and 0.838 (0.763 - 0.913), respectively. Although PSA + PLR had the largest area, there was no statistical significance between PSA + PLR and PSA (p = 0.6992).
CONCLUSIONS: NLR and PLR significantly increase in PCa patients with bone metastases and are valuable in the diagnosis of bone metastases in PCa patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31115239     DOI: 10.7754/Clin.Lab.2018.181040

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  4 in total

1.  Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab.

Authors:  Viktoria Stühler; Lisa Herrmann; Steffen Rausch; Arnulf Stenzl; Jens Bedke
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

2.  Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer.

Authors:  Zhongliang Zhu; Guangyu Yang; Weizhong Wang; Yonglie Zhou; Zhenzhen Pang; Jiawei Liang
Journal:  World J Surg Oncol       Date:  2021-01-24       Impact factor: 2.754

3.  Intramedullary nailing vs modular megaprosthesis in extracapsular metastases of proximal femur: clinical outcomes and complication in a retrospective study.

Authors:  Raffaele Vitiello; Carlo Perisano; Tommaso Greco; Luigi Cianni; Chiara Polichetti; Rocco Maria Comodo; Ivan De Martino; Vincenzo La Vergata; Giulio Maccauro
Journal:  BMC Musculoskelet Disord       Date:  2022-09-13       Impact factor: 2.562

4.  Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy.

Authors:  Pawel Rajwa; Victor M Schuettfort; Fahad Quhal; Keiichiro Mori; Satoshi Katayama; Ekaterina Laukhtina; Benjamin Pradere; Reza Sari Motlagh; Hadi Mostafaei; Nico C Grossmann; Andreas Aulitzky; Andrzej Paradysz; Pierre I Karakiewicz; Harun Fajkovic; Kristin Zimmermann; Axel Heidenreich; Paolo Gontero; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-05-17       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.